Monthly: Immunovaccine drops 3%, 2 months' volume in a month
CANADIAN MONTHLY STOCK REPORT
Immunovaccine (TSX:IMV), Canada's 8th largest Biotechnology company by market cap, has dropped 14.0c (or 2.6%) in the past month to close at CAD5.35. The volume was 2 times average monthly trading of 858,774 shares. Compared with the S&P/TSX 60 Index which rose 5.6 points (or 0.6%) in the month, this represented a relative price change of -3.1%. In the past month the market cap has declined CAD16.7 million (US$12.4 million).